Stay updated with breaking news from Patient Status. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.
The West Midlands Health & Wellbeing Innovation Network are helping the NHS face and solve some of their biggest problems University of Warwick and
This is a quote from a cdc doctor. we have been struck when reviewing the cases by how rapidly patient status deteriorates and results in death. so this is the bottom line, moving forward, get a pfizer moderna, do not get johnson & johnson. if you already had johnson & johnson, unless you had it quite recently, there really is no reason to worry. even if you had it within the past two weeks, these are rare events. if you're concerned at all, look online and see the cdc has put out what signs to look for. jim? >> all right, good to know, elizabeth cohen, thanks so much. experts are warning th...
That were discussed today by the cdc advisors. 17 million people in the united states have received johnson & johnson. 54 of them have developed a rare blood clotting condition, rare but extremely dangerous. nine of those 54 people have died. the people most at risk are women in their 40s. it's two deaths per million for women ages 40 through 49, but you can't predict who is at risk. you can't say, oh, you have this particular medical condition, don't get johnson & johnson. you don't know who is going to be at risk. and patients deteriorate very quickly. a cdc doctor gave these very pointed re...